skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma

Abstract

Purpose: To evaluate the therapeutic results obtained with {sup 192}Ir low-dose-rate interstitial brachytherapy in T2N0 mobile tongue carcinoma. Patients and Methods: Between December 1979 and January 1998, 279 patients with T2N0 mobile tongue carcinoma were treated by exclusive low-dose-rate brachytherapy, with or without neck dissection. {sup 192}Ir brachytherapy was performed according to the 'Paris system' with a median total dose of 60 Gy (median dose rate, 0.5 Gy/h). Results: Overall survival was 74.3% and 46.6% at 2 and 5 years. Local control was 79.1% at 2 years and regional control, respectively, 75.9% and 69.5% at 2 and 5 years (Kaplan-Meier method). Systematic dissection revealed 44.6% occult node metastases, and histologic lymph node involvement was identified as the main significant factor for survival. Complication rate was 16.5% (Grade 3, 2.9%). Half of the patients presented previous and/or successive malignant tumor (ear-nose-throat, esophagus, or bronchus). Conclusion: Exclusive low-dose-rate brachytherapy is an effective treatment for T2 tongue carcinoma. Regional control and survival are excellent in patients undergoing systematic neck dissection, which is mandatory in our experience because of a high rate of occult lymph node metastases.

Authors:
 [1];  [1];  [2];  [1];  [1];  [3];  [1]
  1. Department of Radiotherapy, Centre Oscar Lambret, Lille (France)
  2. Department of Biostatistics, Centre Oscar Lambret, Lille (France)
  3. Department of Head and Neck Surgery, Centre Oscar Lambret, Lille (France)
Publication Date:
OSTI Identifier:
20702151
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 63; Journal Issue: 2; Other Information: DOI: 10.1016/j.ijrobp.2005.02.014; PII: S0360-3016(05)00350-0; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; AUDITORY ORGANS; BRACHYTHERAPY; CARCINOMAS; DOSE RATES; ESOPHAGUS; IRIDIUM 192; LYMPH NODES; METASTASES; NECK; NOSE; PATIENTS; PHARYNX; RADIATION DOSES; TONGUE

Citation Formats

Bourgier, Celine, Coche-Dequeant, Bernard, Fournier, Charles, Castelain, Bernard, Prevost, Bernard, Lefebvre, Jean-Louis, and Lartigau, Eric. Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma. United States: N. p., 2005. Web. doi:10.1016/j.ijrobp.2005.02.014.
Bourgier, Celine, Coche-Dequeant, Bernard, Fournier, Charles, Castelain, Bernard, Prevost, Bernard, Lefebvre, Jean-Louis, & Lartigau, Eric. Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma. United States. https://doi.org/10.1016/j.ijrobp.2005.02.014
Bourgier, Celine, Coche-Dequeant, Bernard, Fournier, Charles, Castelain, Bernard, Prevost, Bernard, Lefebvre, Jean-Louis, and Lartigau, Eric. 2005. "Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma". United States. https://doi.org/10.1016/j.ijrobp.2005.02.014.
@article{osti_20702151,
title = {Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma},
author = {Bourgier, Celine and Coche-Dequeant, Bernard and Fournier, Charles and Castelain, Bernard and Prevost, Bernard and Lefebvre, Jean-Louis and Lartigau, Eric},
abstractNote = {Purpose: To evaluate the therapeutic results obtained with {sup 192}Ir low-dose-rate interstitial brachytherapy in T2N0 mobile tongue carcinoma. Patients and Methods: Between December 1979 and January 1998, 279 patients with T2N0 mobile tongue carcinoma were treated by exclusive low-dose-rate brachytherapy, with or without neck dissection. {sup 192}Ir brachytherapy was performed according to the 'Paris system' with a median total dose of 60 Gy (median dose rate, 0.5 Gy/h). Results: Overall survival was 74.3% and 46.6% at 2 and 5 years. Local control was 79.1% at 2 years and regional control, respectively, 75.9% and 69.5% at 2 and 5 years (Kaplan-Meier method). Systematic dissection revealed 44.6% occult node metastases, and histologic lymph node involvement was identified as the main significant factor for survival. Complication rate was 16.5% (Grade 3, 2.9%). Half of the patients presented previous and/or successive malignant tumor (ear-nose-throat, esophagus, or bronchus). Conclusion: Exclusive low-dose-rate brachytherapy is an effective treatment for T2 tongue carcinoma. Regional control and survival are excellent in patients undergoing systematic neck dissection, which is mandatory in our experience because of a high rate of occult lymph node metastases.},
doi = {10.1016/j.ijrobp.2005.02.014},
url = {https://www.osti.gov/biblio/20702151}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 2,
volume = 63,
place = {United States},
year = {Sat Oct 01 00:00:00 EDT 2005},
month = {Sat Oct 01 00:00:00 EDT 2005}
}